Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program

Rebecca M. Thiede, Supriya Rastogi, Beatrice Nardone, Lauren M. Sadowsky, Stephanie M Rangel, Dennis P West, Bethanee J Schlosser*

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The necessity of serum potassium monitoring for healthy women who are prescribed spironolactone for acne has been debated. The aim of this study was to compare the incidence of hyperkalemia in women 18 to 45 years of age to that in women 46 to 65 years of age, when treated with oral spironolactone for acne. Methods and materials: Data for all women 18 to 65 years of age who were prescribed oral spironolactone by a dermatologist for acne between January 2006 and October 2016 were extracted for analysis. Retrospective data were included for women who exhibited baseline serum potassium within the normal limits and who had repeat serum potassium monitoring within 12 months after initiation of spironolactone. The rate of incident hyperkalemia was determined. Results: Of 618 women who received spironolactone for acne, 133 had serum potassium monitoring both before and after spironolactone initiation. Nine were excluded due to confounding comorbidities. Of the remaining 124 women, the mean age at initiation of spironolactone was 32 years (range, 18-57 years); 112 women were in the 18 to 45 years age group, and 12 were in the 46 to 65 years age group. All women had serum potassium within normal limits at baseline. Women in the 46 to 65 years age group had a significantly higher rate of incident hyperkalemia after spironolactone initiation compared with women 18 to 45 years of age (2 of 12 women [16.7%] vs. 1 of 112 women [< 1%]; p = .0245). Conclusions: Although controversy surrounds the clinical utility of serum potassium monitoring in healthy women exposed to spironolactone for acne, based on the findings from this large patient population, monitoring of serum potassium is warranted for women over 45 years of age given an age-related greater risk of hyperkalemia.

Original languageEnglish (US)
Pages (from-to)155-157
Number of pages3
JournalInternational Journal of Women's Dermatology
Volume5
Issue number3
DOIs
StatePublished - Jul 1 2019

Fingerprint

Spironolactone
Hyperkalemia
Acne Vulgaris
Drug-Related Side Effects and Adverse Reactions
Retrospective Studies
Research
Potassium
Serum
Age Groups
Physiologic Monitoring

Keywords

  • Spironolactone
  • acne
  • female
  • hyperkalemia
  • potassium

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{ec600f13dc7d46aca713e253bd727e2e,
title = "Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program",
abstract = "Purpose: The necessity of serum potassium monitoring for healthy women who are prescribed spironolactone for acne has been debated. The aim of this study was to compare the incidence of hyperkalemia in women 18 to 45 years of age to that in women 46 to 65 years of age, when treated with oral spironolactone for acne. Methods and materials: Data for all women 18 to 65 years of age who were prescribed oral spironolactone by a dermatologist for acne between January 2006 and October 2016 were extracted for analysis. Retrospective data were included for women who exhibited baseline serum potassium within the normal limits and who had repeat serum potassium monitoring within 12 months after initiation of spironolactone. The rate of incident hyperkalemia was determined. Results: Of 618 women who received spironolactone for acne, 133 had serum potassium monitoring both before and after spironolactone initiation. Nine were excluded due to confounding comorbidities. Of the remaining 124 women, the mean age at initiation of spironolactone was 32 years (range, 18-57 years); 112 women were in the 18 to 45 years age group, and 12 were in the 46 to 65 years age group. All women had serum potassium within normal limits at baseline. Women in the 46 to 65 years age group had a significantly higher rate of incident hyperkalemia after spironolactone initiation compared with women 18 to 45 years of age (2 of 12 women [16.7{\%}] vs. 1 of 112 women [< 1{\%}]; p = .0245). Conclusions: Although controversy surrounds the clinical utility of serum potassium monitoring in healthy women exposed to spironolactone for acne, based on the findings from this large patient population, monitoring of serum potassium is warranted for women over 45 years of age given an age-related greater risk of hyperkalemia.",
keywords = "Spironolactone, acne, female, hyperkalemia, potassium",
author = "Thiede, {Rebecca M.} and Supriya Rastogi and Beatrice Nardone and Sadowsky, {Lauren M.} and Rangel, {Stephanie M} and West, {Dennis P} and Schlosser, {Bethanee J}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.ijwd.2019.04.024",
language = "English (US)",
volume = "5",
pages = "155--157",
journal = "International Journal of Women's Dermatology",
issn = "2352-6475",
publisher = "Elsevier BV",
number = "3",

}

Hyperkalemia in women with acne exposed to oral spironolactone : A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. / Thiede, Rebecca M.; Rastogi, Supriya; Nardone, Beatrice; Sadowsky, Lauren M.; Rangel, Stephanie M; West, Dennis P; Schlosser, Bethanee J.

In: International Journal of Women's Dermatology, Vol. 5, No. 3, 01.07.2019, p. 155-157.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hyperkalemia in women with acne exposed to oral spironolactone

T2 - A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program

AU - Thiede, Rebecca M.

AU - Rastogi, Supriya

AU - Nardone, Beatrice

AU - Sadowsky, Lauren M.

AU - Rangel, Stephanie M

AU - West, Dennis P

AU - Schlosser, Bethanee J

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose: The necessity of serum potassium monitoring for healthy women who are prescribed spironolactone for acne has been debated. The aim of this study was to compare the incidence of hyperkalemia in women 18 to 45 years of age to that in women 46 to 65 years of age, when treated with oral spironolactone for acne. Methods and materials: Data for all women 18 to 65 years of age who were prescribed oral spironolactone by a dermatologist for acne between January 2006 and October 2016 were extracted for analysis. Retrospective data were included for women who exhibited baseline serum potassium within the normal limits and who had repeat serum potassium monitoring within 12 months after initiation of spironolactone. The rate of incident hyperkalemia was determined. Results: Of 618 women who received spironolactone for acne, 133 had serum potassium monitoring both before and after spironolactone initiation. Nine were excluded due to confounding comorbidities. Of the remaining 124 women, the mean age at initiation of spironolactone was 32 years (range, 18-57 years); 112 women were in the 18 to 45 years age group, and 12 were in the 46 to 65 years age group. All women had serum potassium within normal limits at baseline. Women in the 46 to 65 years age group had a significantly higher rate of incident hyperkalemia after spironolactone initiation compared with women 18 to 45 years of age (2 of 12 women [16.7%] vs. 1 of 112 women [< 1%]; p = .0245). Conclusions: Although controversy surrounds the clinical utility of serum potassium monitoring in healthy women exposed to spironolactone for acne, based on the findings from this large patient population, monitoring of serum potassium is warranted for women over 45 years of age given an age-related greater risk of hyperkalemia.

AB - Purpose: The necessity of serum potassium monitoring for healthy women who are prescribed spironolactone for acne has been debated. The aim of this study was to compare the incidence of hyperkalemia in women 18 to 45 years of age to that in women 46 to 65 years of age, when treated with oral spironolactone for acne. Methods and materials: Data for all women 18 to 65 years of age who were prescribed oral spironolactone by a dermatologist for acne between January 2006 and October 2016 were extracted for analysis. Retrospective data were included for women who exhibited baseline serum potassium within the normal limits and who had repeat serum potassium monitoring within 12 months after initiation of spironolactone. The rate of incident hyperkalemia was determined. Results: Of 618 women who received spironolactone for acne, 133 had serum potassium monitoring both before and after spironolactone initiation. Nine were excluded due to confounding comorbidities. Of the remaining 124 women, the mean age at initiation of spironolactone was 32 years (range, 18-57 years); 112 women were in the 18 to 45 years age group, and 12 were in the 46 to 65 years age group. All women had serum potassium within normal limits at baseline. Women in the 46 to 65 years age group had a significantly higher rate of incident hyperkalemia after spironolactone initiation compared with women 18 to 45 years of age (2 of 12 women [16.7%] vs. 1 of 112 women [< 1%]; p = .0245). Conclusions: Although controversy surrounds the clinical utility of serum potassium monitoring in healthy women exposed to spironolactone for acne, based on the findings from this large patient population, monitoring of serum potassium is warranted for women over 45 years of age given an age-related greater risk of hyperkalemia.

KW - Spironolactone

KW - acne

KW - female

KW - hyperkalemia

KW - potassium

UR - http://www.scopus.com/inward/record.url?scp=85066426138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066426138&partnerID=8YFLogxK

U2 - 10.1016/j.ijwd.2019.04.024

DO - 10.1016/j.ijwd.2019.04.024

M3 - Article

C2 - 31360748

AN - SCOPUS:85066426138

VL - 5

SP - 155

EP - 157

JO - International Journal of Women's Dermatology

JF - International Journal of Women's Dermatology

SN - 2352-6475

IS - 3

ER -